 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H25N |
| Molar mass | 327.471 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) | |
JWH-175 is a drug from the naphthylmethylindole family which acts as acannabinoidreceptoragonist. It was invented by the scientistJohn W. Huffman and colleagues atClemson University. JWH-175 is closely related to the widely used cannabinoiddesigner drugJWH-018, but with theketone bridge replaced by a simplermethylene bridge. It is several times weaker than JWH-018, having abinding affinity at the CB1 receptor of 22 nM, though some derivatives substituted at the 4-position of the naphthyl ring have potency more closely approaching that of the equivalent naphthoylindoles.[1] This makes JWH-175 considerably less potent than most synthetic cannabinoid drugs used insynthetic cannabis blends, and it is unclear if JWH-175 has ever been used for this purpose. However it has still been explicitly banned in several jurisdictions including Russia and some Australian states, in order to stop its potential use as an ingredient in such products. In the United States, all CB1 receptor agonists of the 3-(1-naphthylmethane)indole class such as JWH-175 areSchedule I Controlled Substances.[2]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
